Drug Profile
Research programme: multiple sclerosis therapeutics - Cleveland Clinic/Sanofi
Alternative Names: MS therapeutics - Cleveland Clinic Mellen Center for Multiple Sclerosis/SanofiLatest Information Update: 31 Mar 2022
Price :
$50
*
At a glance
- Originator Cleveland Clinic; Genzyme Corporation
- Developer Cleveland Clinic; Sanofi
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Multiple sclerosis
Most Recent Events
- 28 Dec 2018 No recent reports of development identified for research development in Multiple-sclerosis in USA
- 30 Apr 2014 Early research in Multiple sclerosis in USA (unspecified route)